Prognostic impact of highly active antiretroviral therapy in HIV-related Hodgkin's disease

AIDS

Volumn 16, Issue 14, 2002, Pages 1973-1976

  Ribera, Josep Mara ^a   Navarro, Jos Toms ^a   Oriol, Albert ^a   López Guillermo, Armando ^b   Sureda, Anna ^c   Abella, Eugenia ^d   Hernández Rivas, Jose Angel ^e   Xicoy, Blanca ^a   Grau, Javier ^a   Batlle, Montserrat ^a   Feliu, Evarist ^a  

^a HOSPITAL UNIVERSITARI GERMANS TRIAS I PUJOL   (Spain)

^b HOSPITAL CLÍNIC   (Spain)

^c HOSPITAL DE LA SANTA CREU I SANT PAU   (Spain)

^d HOSPITAL DEL MAR   (Spain)

^e HOSPITAL DE MATARÓ   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

BLEOMYCIN; DACARBAZINE; DIDANOSINE; DOXORUBICIN; INDINAVIR; LAMIVUDINE; NELFINAVIR; PROTEINASE INHIBITOR; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; SAQUINAVIR; STAVUDINE; VINBLASTINE; ZALCITABINE; ZIDOVUDINE;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; EVALUATION; FEMALE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HODGKIN DISEASE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MALE; NONHODGKIN LYMPHOMA; PRIORITY JOURNAL; PROGNOSIS; SURVIVAL; TREATMENT OUTCOME;

ADULT; ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; FEMALE; HIV INFECTIONS; HODGKIN DISEASE; HUMANS; LYMPHOMA, NON-HODGKIN; MALE; MIDDLE AGED; PROGNOSIS; RETROSPECTIVE STUDIES; RISK FACTORS; SURVIVAL; TREATMENT OUTCOME;

EID: 0037183961     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002030-200209270-00020     Document Type: Article

References (19)

1. Evison J, Jost J, Ledergerber B, Jost L, Strasser F, Weber R. HIV-associated non-Hodgkin's lymphoma: highly active antiretroviral therapy improves remission rate of chemotherapy. AIDS 1999, 13:732-734.
2. Navarro JT, Ribera JM, Oriol A, et al. Influence of highly active antiretroviral therapy (HAART) on response to treatment and survival in patients with acquired immunodeficiency syndrome-related non-Hodgkin's lymphoma treated with cyclophosphamide, hydroxydoxorubicin, vincristine and prednisone. Br J Haematol 2001, 112:909-915.
3. Vaccher E, Spina M, Di Gennaro D, et al. Concomitant cyclophosphamide, doxorubicin, vincristine and prednisone chemotherapy plus highly active antiretroviral therapy in patients with human immunnodeficiency virus-related, non-Hodgkin lymphoma. Cancer 2001, 91:155-163.
4. Tirelli U, Bernardi D. Impact of HAART on the clinical management of AIDS-related cancers. Eur J Cancer 2001, 37:1320-1324.
5. Hoffmann C, Tabrizian S, Wolf E, et al. Survival of AIDS patients with primary central nervous system lymphoma is dramatically improved by HAART-induced immune recovery. AIDS 2001, 15:2119-2127.
6. Antinori A, Cingolani A, Alba L, et al. Better response to chemotherapy and prolonged survival in AIDS-related lymphomas responding to highly active antiretroviral therapy. AIDS 2001, 15:1483-1491.
7. Harris NL, Jaffe ES, Stein H, et al. A Revised European-American Classification of Lymphoid Neoplasms: a proposal from the International Lymphoma Study Group. Blood 1994, 84:1361-1392.
8. Carbone PP, Kaplan HS, Musshoff K, Smithers DW, Tubiana M. Report of the committee on Hodgkin's disease staging classification. Cancer Res 1971, 31:1860-1861.
9. Hasenclever D, Diehl V, for the International Prognostic Factors Project on Advanced Hodgkin's Disease. A prognostic score for advanced Hodgkin's disease. N Engl J Med 1998, 339:1506-1514.
10. Cheson BD, Horning SJ, Coiffier B, et al. Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. J Clin Oncol 1999, 17:1244-1253.
11. Frisch M, Biggar RJ, Engels EA, Goedert JJ. Association of cancer with AIDS-realted immunosuppression in adults. JAMA 2001, 285:1736-1745.
12. Tirelli U, Errante D, Dolcetti R, et al. Hodgkin's disease and human immunodeficiency virus infection: clinicopathologic and virologic features of 114 patients from Italian Cooperative Group on AIDS and Tumors. J Clin Oncol 1995, 13:1758-1767.
13. Spina M, Vaccher E, Nasti G, Tirelli U. Human immunodeficiency virus-associated Hodgkin's disease. Semin Oncol 2000, 27:480-488.
14. Re A, Casari S, Cattaneo C, et al. Hodgkin's disease developing in patients infected by human immunodeficiency virus results in clinical features and a prognosis similar to those in patients with human immunodeficiency virus-related non Hodgkin's lymphoma. Cancer 2001, 92:2739-2745.
15. Ratner L, Lee J, Tang S, et al. Chemotherapy for human immunodeficiency virus-associated non-Hodgkin's lymphoma in combination with highly active antiretroviral therapy. J Clin Oncol 2001, 19:2171-2178.
16. Spina M, Gabarre J, Vaccher E. Feasibility of the integration of Stanford V chemotherapy (CT) regimen with highly active antiretroviral therapy (HAART) and G-CSF in patients with Hodgkin disease and HIV infection. In: 5th International AIDS Malignancy Conference. Bethesda, MD, 23-25 April 2001 [Abstract 24].
17. Hoffmann C, Tabrizian S, Wolf E, et al. Survival of AIDS patients with primary central nervous system lymphoma is dramatically improved by HAART-induced immune recovery. AIDS 2001, 15:2119-2127.
18. Antinori A, Cingolani A, Alba L, et al. Better response to chemotherapy and prolonged survival in AIDS-related lymphomas responding to highly active antiretroviral therapy. AIDS 2001, 15:1483-1491.
19. Navarro JT, Ribera JM, Oriol A, et al. Favorable impact of virological response to highly active antiretroviral therapy on survival in patients with AIDS-related non-Hodgkin's lymphoma. Leuk Lymphoma 2002, 43:1837-1842.